Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04579120 · ClinicalTrials.gov registry record
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
A clinical trial of Alzheimer Disease, sponsored by Tammie L. S. Benzinger, MD, PhD.
- Recruiting
- Registry status
- 650
- Enrollment target
- 1
- Study location
NCT04579120: Recruiting study of Alzheimer Disease, sponsored by Tammie L. S. Benzinger, MD, PhD.
NCT04579120 is a study of Alzheimer Disease that is actively recruiting participants, run by Tammie L. S. Benzinger, MD, PhD. The registered enrollment target is 650 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04579120, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Tammie L. S. Benzinger, MD, PhD.
- RECRUITING
- Registry status
- 650 participants
- Enrollment target
- 1
- Study location
Study Summary
To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).
Primary Outcome
This Project aims to identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD). This will be done by comparing imaging biomarkers seen with amyloid PET and the tracer C-11 PIB at baseline to imaging biomarkers collected longitudinally, at years 1, 2, and/or 3.
Conditions Studied
Interventions
- DRUG F 18 AV-1451 (Flortaucipir)
- DRUG [11C]-Pittsburgh Compound B ([11C]PiB)
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2025-12 |
What NCT04579120 shows while recruiting
NCT04579120 is an observational study that tracks outcomes without assigning an intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which F 18 AV-1451 (Flortaucipir) is the first listed.
NCT04579120 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT04579120 about?
NCT04579120 is a clinical study titled "Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)". To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).
What is the current status of trial NCT04579120?
This trial is currently recruiting. The enrollment target is 650 participants. The study started on 2021-09-01. Estimated completion is 2025-12.
What conditions does trial NCT04579120 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT04579120?
The interventions under investigation include: F 18 AV-1451 (Flortaucipir) (DRUG), [11C]-Pittsburgh Compound B ([11C]PiB) (DRUG).
Who is sponsoring clinical trial NCT04579120?
This trial is sponsored by Tammie L. S. Benzinger, MD, PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04579120 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04579120's enrollment target sits among peer trials
650 43rd of 306 higher than 264 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
- NCT05046600 · 650 participants
Registry of Arthrex Hand and Wrist Products
- NCT05253235 · 650 participants · NA
Health and Resilience Projects: Foundations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI